Diabetic polyneuropathy: from science to practice

Abstract

Diabetes mellitus (DM) is one of the most common causes of polyneuropathy worldwide. In accordance with the modern classification, there are typical and atypical forms of generalized diabetic polyneuropathy (DPN) some of which have differing pathogenesis and clinical manifestations. The questions of pathogenesis and diagnostic principles for the most common form - typical DPN - are considered. The main approaches to the treatment of patients with DPN are discussed: 1) glycemic control, 2) lifestyle recommendations, 3) pathogenetic therapy, 4) symptomatic treatment. Pathogenetic therapy includes administration of alpha-lipoic acid (ALA). Berlithion® is an ALA widely used in neurological practice which proved to be effective and demonstrated high safety profile in the treatment of DPN.

Keywords

• диабетическая полинейропатия
• патогенез
• диагностика
• лечение альфа-липоевая кислот
• diabetic polyneuropathy
• pathogenesis
• diagnosis
• treatment
• alpha-lipoic acid